Induction of anti-tumor immunity elicited by tumor cells expressing a murine LFA-3 analog via a recombinant vaccinia virus

Human Gene Therapy

Volumn 10, Issue 4, 1999, Pages 623-631

  Lorenz, Matthias G O ^a   Kantor, Judy A ^a   Schlom, Jeffrey ^a   Hodge, James W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3;

ANIMAL CELL; ARTICLE; CANCER MODEL; CELL ADHESION; CELL PROLIFERATION; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; GAMMA IRRADIATION; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; MEMORY CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POXVIRUS; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY; VACCINIA VIRUS; VIRUS RECOMBINANT;

ADENOCARCINOMA; ANIMALS; ANTIGENS, CD58; BASE SEQUENCE; CELL DIVISION; COLONIC NEOPLASMS; DNA PRIMERS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECOMBINATION, GENETIC; T-LYMPHOCYTES; VACCINIA VIRUS;

ANIMALIA; DNA VIRUSES; MURINAE; POXVIRIDAE; VACCINIA; VACCINIA VIRUS;

EID: 0033104972     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950018698     Document Type: Article

References (32)

1. ALLISON, J.P., HURWITZ, A.A., and LEACH, D.R. (1995). Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr. Opin. Immunol. 7, 682-686.
2. ALTEVOGT, P., MICHAELIS, M., and KYEWSKI, B. (1989). Identical forms of the CD2 antigen expressed by mouse T and B lymphocytes. Eur. J. Immunol. 19, 1509.
3. ANASETTI, C., MARTIN, P.J., JUNE, C.H., HELLSTROM, K.E., LEDBETTER, J.A., RABINOVITCH, P.S., MORISHITA, Y., HELLSTROM, I., and HANSEN, J.A. (1987). Induction of calcium flux and enhancement of cytolytic activity in natural killer cells by cross-linking of the sheep erythrocyte binding protein (CD2) and the Fc-receptor (CD16). J. Immunol. 139, 1772-1779.
4. AYROLDI, E., MIGLIORATI, G., CANNARILE, L., MORACA, R., DELFINO, D.V., and RICCARDI, C. (1997). CD2 rescues T cells from T-cell receptor/CD3 apoptosis: A role for the Fas/Fas-L system. Blood 89, 3717-3726.
5. CARROLL, M.W., and MOSS, B. (1997). Poxviruses as expression vectors. Curr. Opin. Biotechnol. 97, 573-577.
6. CAVALLO, F., MARTIN-FONTECHA, A., BELLONE, M., HELTAI, S., GATTI, E., TORNAGHI, P., FRESCHI, M., FORNI, G., DELLABONA, P., and CASORATI, G. (1995). Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur. J. Immunol. 25, 1154-1162.
7. CHAVIN, K.D., QIN, L., LIN, J., KAPLAN, A.J., and BROMBERG, J.S. (1993). Anti-CD2 and anti-CD3 monoclonal antibodies synergize to prolong allograft survival with decreased side effects. Transplantation 55, 901-908.
8. CHEN, L., McGOWAN, P., ASHE, S., JOHNSTON, J., LI, Y., HELLSTROM, I., and HELLSTROM, K.E. (1994). Tumor immunogenicity determines the effect of B7 costimulation of T cell-mediated tumor immunity. J. Exp. Med. 179, 523-532.
9. DALGLEISH, A.G. (1996). Co-stimulatory molecules and their role in tumor immunity. In Tumor Immunology: Immunotherapy and Cancer Vaccines. B. Dalgleish, ed. (Cambridge University Press, New York) pp. 185-198.
10. DAVIS, S.J., and VAN DER MERWE, P.A. (1996). The structure and ligand interactions of CD2: Implications for T-cell function. Immunol. Today 17, 177-187.
11. FOX, B.A., SPIESS, P.J., KASID, A., PURI, R., MULE, J.J., WEBER, J.S., and ROSENBERG, S.A. (1990). In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes. J. Biol. Response Modif. 9, 499-511.
12. GENARO, A.M., GONZALO, J.A., BOSCA, L., and MARTINEZ, C. (1994). CD2-CD48 interaction prevents apoptosis in murine B lymphocytes by up-regulating bcl-2 expression. Eur. J. Immunol. 24, 2515-2521.
13. GOLLOB, J.A., LI, J., REINHERZ, E.L., and RITZ, J. (1995). CD2 regulates responsiveness of activated T cells to interleukin. J. Exp. Med. 182, 721-731.
14. GUCKEL, B., BEREK, C., LUTZ, P., ALTEVOGT, V., SCHIRRMACHER, V., and KYEWSKI, B.A. (1991). Anti-CD2 antibodies induce T cell unresponiveness in vivo. J. Exp. Med. 176, 1241-1240.
15. HARRINGTON, N.P., CHAMBERS, K.A., ROSS, W.M., and FILION, L.G. (1997). Radiation damage and immune suppression in splenic mononuclear cell populations. Clin. Exp. Immunol. 107, 417-424.
16. KANTOR, J., IRVINE, K., ABRAMS, S., SNOY, P., OLSEN, R., GREINER, J., KAUFMAN, H., EGGENSPERGER, D., and SCHLOM, J. (1992). Immunogenicity and safety of a recombinant vaccinia virus vaccine expression the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res. 52, 6917-6925.
17. KARMANN, K., HUGHES, C.C., FANSLOW, W.C., and POBER, J.S. (1996). Endothelial cells augment the expression of CD40 ligand on newly activated human CD4+ T cells through a CD2/LFA-3 signaling pathway. Eur. J. Immunol. 26, 610-617.
18. KATO, K., KOYANAGI, M., OKADA, H., TAKANASHI, T., WONG, Y.W., WILLIAMS, A.F., OKUMURA, K., and YAGITA, H. (1992). CD48 is a counter-receptor for mouse CD2 and is involved in T cell activation. J. Exp. Med. 176, 1241-1249.
19. LI, Y., HELLSTROM, K.E., NEWBY, S.A., and CHEN, L. (1996). Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors. J. Exp. Med. 183, 639-644.
20. LORENZ, M.G.O., KANTOR, J.A., SCHLOM, J., and HODGE, J.W. (1999). Antitumor immunity elicited by vaccinia virus expressing CD70 (CD27L). Hum. Gene Ther. (in press).
21. MEUER, S.C., HUSSEY, R.C., FABBI, M., FOX, D., ACUTO, O., FITZGERALD, K.A., HODGDON, J.C., PROTENTIS, J.P., SCHLOSSMAN, S.F., and REINHERZ, E.L. (1984). An alternative pathway of T-cell activation: A functional role for the 50 kd T11 sheep erythrocyte receptor protein. Cell 36, 897.
22. NEILAND, J.D., GRAUS, Y.F., DORTMANS, Y.E., KREMERS, B.L., and KRUISBEEK, A.M. (1998). CD40 and CD70 co-stimulate a potent in vivo antitumor T cell response. J. Immunother. 21, 225-236.
23. OSTRAND-ROSENBERS, S. (1994). Tumor immunotherapy: The tumor cell as antigen-presenting cell. Curr. Opin. Immunol. 6, 722-727.
24. RAMARATHINAM, L., CASTLE, M., WU, Y., and LIU, Y. (1994). T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: An important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J. Exp. Med. 179, 1205-1214.
25. RESTIFO, N. (1996). The new vaccines: Building viruses that elicit antitumor immunity. Curr. Opin. Immunol. 8, 658-663.
26. ROBEY, E., and ALLISON, J.P. (1995). T-cell activation: Integration of signals from the antigen receptor and costimulatory molecules. Immunol. Today 16, 306-310.
27. SELVARAJ, P., PLUNKETT, M.L., DUSTIN, M., SANDERS, M.E., SHAW, S., and SPRINGER, T.A. (1987). The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3. Nature (London) 326, 400-403.
28. TOWNSEND, S.E., SU, F.W., ATHERTON, J.M., and ALLISON, J.P. (1994). Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 54, 6477-6483.
29. VAN DE GRIEND, R.J., BOLHUIS, R.L., STOTER, G., and ROOZEMOND, R.C. (1987). Regulation of cytolytic activity in CD3-and CD3+ killer cell clones by monoclonal antibodies (anti-CD16, anti-CD2, anti-CD3) depends on subclass specificity of target cell lgG-FcR. J. Immunol. 138, 3137-3144.
30. WONG, Y.W., WILLIAMS, A.F., KINGSMORE, S.F., and SELDIN, M.F. (1990). Structure, expression, and genetic linkage of the mouse BCM1 (OX45 or Blast-1) antigen. Evidence for genetic duplication giving rise to the BCM1 region on mouse chromosome 1 and the CD2/LFA3 region on mouse chromosome 3. J. Exp. Med. 171, 2115-2130.
31. YAGITA, H., OKUMURA, K., and NAKAUCHI, H. (1989). Molecular cloning of the murine homologue of CD2. Homology of the molecule to its human counterpart T11. J. Immunol. 140, 1321.
32. YU, X., ABE, R., and HODES, R.J. (1998). The role of B7-CD28 co-stimulation in tumor rejection. Int. Immunol. 10, 791-797.